TZTao Zeng

Tao Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tao Zeng has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An extraction-free one-pot immunomagnetic-RPA-CRISPR/Cas13a platform for ultrasensitive detection of exosomal PD-L1

    by Hansen Shi, Jiayi Chen, Xiaocong Lin, Yaning Zhang, Haiqi Wu, Biyun Zeng, Peijun Zhang, Qianying Luo, Tiancai Liu, Tao Zeng

  • CRISPR-Cas12a-based liquid biopsy technology: challenges in large-scale clinical application

    by Yaning Zhang, Xiaocong Lin, Hansen Shi, Zhibing Chen, Qianying Luo, Haiqi Wu, Tao Zeng


  • Aptamer-based CRISPR–Cas12a fluorescent biosensors for serum biomarker detection

    by Zhibing Chen, Haiqi Wu, Lok Ting Chu, Juncheng Lin, Yaning Zhang, Xiaocong Lin, Tao Zeng

    This review summarises the recent advances in aptamer-integrated CRISPR–Cas12a fluorescent biosensors, highlighting their sensing architectures, signal-transduction strategies and the emerging trends for serum biomarker detection.


  • Open Access

    Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma

    by Hansen Shi, Peijun Zhang, Qiping Wei, Huixiang He, Haiqi Wu, Tianyin Xiao, Tiancai Liu, Tao Zeng

    Hepatocellular carcinoma (HCC) is a malignant tumour with high global incidence and mortality, featuring limited therapeutic options and poor prognosis, which necessitates novel prognostic biomarkers. The immune checkpoint molecule CD274 (Programmed Death-Ligand 1, PD-L1) correlates with poor prognosis in most solid tumours, yet its prognostic value in HCC remains controversial, and circulating levels are unclear. This study aimed to multi-dimensionally investigate CD274's expression patterns and clinical significance in HCC. Bioinformatics analyses were performed on The cancer genome atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases to screen differentially expressed genes, with functional and pathway annotations via Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and Single-Sample Gene Set Enrichment Analysis (ssGSEA). Survival analysis and univariate/multivariate Cox proportional hazards regression models were used to assess the prognostic value of CD274. PD-L1 protein expression was validated by immunohistochemistry (IHC) on HCC tissue microarrays. Serum PD-L1 concentrations were detected by ELISA in treatment-naive HCC patients and healthy controls. CD274 was lowly expressed in HCC tissues versus normal ones, and its expression correlated with TNF-α/NF-κB, complement, IFN-γ, adipogenesis and oxidative phosphorylation pathways, as well as lymphocyte-mediated immunity, immune globulin complexes and antigen binding. High CD274 expression negatively correlated with Th17 cells but positively with helper T cells, activated dendritic cells (aDCs), Th1 cells, T cells and macrophages via ssGSEA. Patients with high CD274 expression had longer overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI); multivariate Cox regression confirmed CD274 as an independent protective factor for DSS. PD-L1 protein expression showed no significant difference between HCC and normal liver tissues. Serum PD-L1 median was 349.6 pg/mL in HCC patients, significantly higher than 181.3 pg/mL in healthy controls. This study first identifies a unique "low tissue expression and elevated peripheral blood level" pattern of CD274 in HCC, with intratumoural high expression correlating with favourable prognosis. CD274 may exert distinct roles in local tumour and systemic immune regulation, and serum CD274 is a promising prognostic biomarker for HCC worthy of further research.

  • Open Access

    Multi‐Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma

    by Hansen Shi, Peijun Zhang, Jiayi Chen, Hua Li, Xiaohuai Zhang, Biyun Zeng, Tiancai Liu, Tao Zeng

    Lung adenocarcinoma (LUAD) is a predominant form of lung cancer with poor prognosis due to early diagnosis challenges and treatment resistance. Thymidylate synthetase (TYMS), a key enzyme in DNA synthesis, has been associated with poor prognosis in multiple cancers, yet its multi‐omics characteristics in LUAD remain systematically uncharacterized. This study focuses specifically on LUAD, integrating transcriptomic, proteomic, and genomic data to elucidate TYMS expression patterns, prognostic value, immune microenvironment interactions, and therapeutic potential. Using data from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumour Analysis Consortium (CPTAC), the Genome‐Tissue Expression Project (GTEx), the Gene Expression Profile Interaction Analysis (GEPIA2), etc., we conducted comprehensive bioinformatics analyses of TYMS in LUAD. TYMS showed significant overexpression at both mRNA and protein levels in LUAD tissue. High TYMS expression correlated with earlier tumour staging, higher histological grade, and poor prognosis. Functional enrichment analysis revealed TYMS involvement in p53/Rb and mammalian Target of Rapamycin (mTOR) signalling pathways. TYMS expression was associated with immune cell infiltration, showing negative correlation with B‐cell activity and positive correlation with neutrophil infiltration, as well as significant association with Cytotoxic T Lymphocyte‐Associated Protein 4 (CTLA4), Programmed Death‐1 (PDCD1, PD‐1), and Interleukin‐6 (IL‐6). Somatic copy number variation (SCNA) analysis indicated that TYMS amplification was linked to poor prognosis and enriched in the folate metabolism pathways. Drug sensitivity analysis demonstrated that high TYMS expression positively correlated with sensitivity to Afatinib and Gefitinib, but negatively correlated with Methotrexate and Vorinostat. In conclusion, TYMS is upregulated in LUAD and may serve as an independent prognostic biomarker and therapeutic target.

  • Regulation of EMT and cholangiocarcinoma metastasis by KIN17 through the mTOR signaling pathway

    by Yuxia Yang, Qianying Luo, Chuhong Huang, Xiaocong Lin, Lok Ting Chu, Qiuyan Li, Jinjing Tang, Tao Zeng


  • CRISPR-Cas12a/Cas13a in cancer molecular diagnosis

    by Juncheng Lin, Yuyuan Wang, Biyun Zeng, Zhibing Chen, Xiaocong Lin, Tao Zeng


  • Open Access

    High Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma

    by Zhenkai Chen, Ruiqi Su, Liwen Jiang, Lina Yang, Xiaocong Lin, Qiyuan Huang, Kashif Rafiq Zahid, Yunen Lin, Tao Zeng

    Background: Kin17 is critical in regulating the proliferation and metastasis of tumors in various malignancies. However, the relationship between Kin17 expression, clinicopathologic features, and esophageal squamous cell carcinoma (ESCC) prognosis remains unclear. Methods: The analysis of Kin17 messenger RNA (mRNA) expression involved the utilization of data from The Cancer Genome Atlas (TCGA) dataset through the platforms the University of ALabama at Birmingham CANcer data analysis portal (UALCAN) and the Gene Expression Omnibus (GEO). To determine the expression levels of Kin17 in tissues, immunohistochemistry was conducted. Using Pearson's chi-square test, the relationship between Kin17 expression and clinicopathological variables was evaluated. Cox proportional hazard models (both univariate and multivariate), receiver operating characteristic (ROC) curves, and Kaplan–Meier survival curves were used to analyze survival. Results: In both the TCGA and GEO datasets, the mRNA level of Kin17 was greater in tumor tissues when compared to tumor-adjacent tissues ( P < 0.001). Similarly, there was a significant expression of Kin17 ( P < 0.0001) in ESCC tissues. Elevated Kin17 expression correlated significantly with increased Ki-67 levels ( P < 0.001), advanced pathological tumor node metastasis stage ( P = 0.01), and positive lymph node metastasis ( P = 0.02). According to univariate and multivariate Cox models, high Kin17 expression was associated with poorer progression-free survival (PFS) (hazard ratio (HR): 1.990, 95% confidence interval (CI): (1.040–3.810)), and Kin17 was an independent prognostic variable for overall survival (OS) (HR: 2.321, 95% CI: (1.056–5.101)). ROC curve showed that the area under the curve for predicting PFS and OS using the combination of Kin17 and K-i67 was 0.7088 and 0.7031, respectively. High Kin17 expression was associated with unfavorable PFS (HR: 2.009, 95% CI: (1.059–3.811)) and OS (HR: 2.997, 95% CI: (1.488–6.040)). Conclusions: Kin17 is abundantly expressed in ESCC tissues and is potentially useful for prognostic evaluation and as a target for therapeutic interventions in ESCC.

  • Immuno-PCR: A high-sensitivity approach for biomarker analysis

    by Hansen Shi, Biyun Zeng, Qiping Wei, Zhu Yuan, Jingjie Peng, Peijun Zhang, Tiancai Liu, Tao Zeng


  • Open Access

    Exploring the diagnostic potential of plasma circ-CCDC66 in colorectal cancer

    by Zhuoting Han, Lok Ting Chu, Xiaocong Lin, Tao Zeng

    Owing to the subtle symptoms and low sensitivity of colorectal cancer (CRC), such as rectal bleeding, anemia, and abdominal pain, CRC generally occurs in late stages. This leads to delayed diagnosis and reduced treatment efficiency. Therefore, novel and effective CRC markers are needed. In this study, we conducted circRNA expression profiling on GSE datasets and identified circ-CCDC66 as a potential marker. Through qPCR analysis of plasma samples from 50 CRC patients, 50 with colorectal polyps, and 50 healthy individuals, circ-CCDC66 emerged as a promising biomarker for CRC detection capable of identifying polyps among healthy individuals. Furthermore, plasma circ-CCDC66 levels exhibited superior diagnostic accuracy, with an AUC of 0.920, compared to traditional markers, such as serum CEA and CA19-9. Remarkably, the combined detection of circ-CCDC66, CEA, and CA19-9 further increased the AUC for distinguishing the colorectal polyps’ group from the healthy control group to 0.991, with sensitivity and specificity increasing to 98% and 96%, respectively. Additionally, a circ-CCDC66-miRNA-mRNA regulatory network was established to provide insight into how circ-CCDC66 influences CRC pathways. This pioneering study highlights circ-CCDC66’s clinical relevance as a blood-based diagnostic marker for CRC and offers valuable insights into future developments in the diagnosis and treatment of the disease.